questionText: To ask the Secretary of State for Health and Social Care, when he plans to publish real world evidence on the effectiveness of the respiratory syncytial virus vaccine in the 75-80 cohort; how much such evidence has been collected; and whether such evidence from other countries has been taken into account in consideration of extending eligibility for that vaccine.
answerText: The UK Health Security Agency is working on vaccine effectiveness analysis within the 75 to 80-year-old age group for this winter season 2024 to 2025. We are collating data on respitatory syncytial virus (RSV) hospitalisations in England and general pract...
heading: Respiratory Syncytial Virus: Vaccination